<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01070524</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-0909-PR-0020</org_study_id>
    <secondary_id>2009-013759-32</secondary_id>
    <nct_id>NCT01070524</nct_id>
  </id_info>
  <brief_title>Cross-over Study to Evaluate the Effect on Trough Forced Expiratory Volume in One Second (FEV1) After 4 Weeks Treatment With CHF 5188 pMDI qd in Adult Patients With Persistent Asthma</brief_title>
  <official_title>A Randomised, Double-blind, Active-controlled, 3 Way Cross-over Study to Evaluate the Effect on Trough FEV1 After 4 Weeks Treatment With CHF 5188 pMDI qd (Fixed Combination Budesonide / Carmoterol) in Adult Patients With Moderate or Severe Persistent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cross-over study to evaluate the effect on trough FEV1 after 4 weeks treatment with CHF5188
      pMDI qd in adult patients with persistent asthma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomised, double-blind, multinational, multicentre, active-controlled, 3-way cross-over
      study to evaluate the effect on trough FEV1 after 4 weeks treatment with CHF5188 pMDI qd in
      adult patients with moderate or severe persistent asthma
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trough FEV1 (mean 23h-24h FEV1)</measure>
    <time_frame>after day 28 dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 and forced vital capacity (FVC) (mean 23h-24h)</measure>
    <time_frame>after day 1 dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC (mean 23-24h)</measure>
    <time_frame>after day 28 dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 and FVC</measure>
    <time_frame>on day 1 and day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC0-24</measure>
    <time_frame>after day 1 and day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">113</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>CHF 5188 pMDI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide extrafine pMDI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Seretide(r) Evohaler(r)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 5188 pMDI</intervention_name>
    <description>CHF 5188: fixed combination budesonide/carmoterol</description>
    <arm_group_label>CHF 5188 pMDI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide extrafine pMDI</intervention_name>
    <description>Budesonide extrafine pMDI</description>
    <arm_group_label>Budesonide extrafine pMDI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seretide(r) Evohaler(r)</intervention_name>
    <description>Seretide(r) Evohaler(r): fixed combination fluticasone/salmeterol</description>
    <arm_group_label>Seretide(r) Evohaler(r)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate or severe asthma partly controlled with ICS or ICS/LABA

          -  FEV1 ≥ 60% and ≤ 90% of predicted for the patient normal value

        Exclusion Criteria:

          -  Diagnosis of COPD

          -  History or current evidence of significant cardiovascular disease

          -  Uncontrolled concomitant disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dave Singh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Medicines Evaluation Unit Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Medicines Evaluation Unit Ltd, The Langley Building, Southmoor Road</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013759-32</url>
    <description>Study Record on EU Clinical Trials Register including results</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2010</study_first_submitted>
  <study_first_submitted_qc>February 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2010</study_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <responsible_party>
    <name_title>Dr. Dave Singh</name_title>
    <organization>The Medicines Evaluation Unit Ltd</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

